Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 88 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chronic Rejection Clear all

Conditions: End Stage Renal Disease, Rejection of Renal Transplant
Interventions: Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]; Drug
Lead sponsor: Lorenzo Gallon; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant
Interventions: Donor-derived cell-free DNA; Diagnostic Test
Lead sponsor: Paris Translational Research Center for Organ Transplantation; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions: Pirfenidone Capsule, Placebo Capsule; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions: LAM-001, Placebo; Drug
Lead sponsor: Steven Hays, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Rejection
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions: Placebo, EZ-2053, EZ-2053 5mg/kg; Biological
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Conditions: Prevention of Rejection in Kidney Transplant
Interventions: AT-1501; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Kidney Transplant Rejection
Interventions: AT-1501, Tacrolimus; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 22 more

Conditions: Kidney Transplant Failure and Rejection
Interventions: AlloSure ddcfDNA assay, AlloMap assay, Inflammatory Cytokines, Immune Cell Phenotypes; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: End-stage Renal Disease, Renal Transplantation, Kidney Transplantation
Interventions: Conditioning Regimen; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Transplantation
Interventions: Kidney biopsy; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more

Conditions: Gastroesophageal Reflux
Interventions: esophagogastroduodenoscopy, Standard GER questionnaire (RDQ), Scintigraphic evaluation of solid gastric emptying, Twenty-four hour ambulatory pH testing, Esophageal manometry testing; Procedure · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Failure, Chronic
Interventions: Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Antibody-mediated Rejection in Kidney Transplant
Interventions: Chronic active AMR group, Non-Chronic active AMR group; Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • St Louis, Missouri

Conditions: End Stage Renal Disease
Interventions: Tacrolimus, Envarsus XR; Drug
Lead sponsor: Roberto Gedaly; Other
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Rejection Chronic Renal, Kidney Transplant Rejection
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Transplant Rejection
Interventions: Hyperpolarized 129-Xenon (MagniXene) MRI of the lung; Combination Product
Lead sponsor: Xemed LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
Interventions: Rituximab plus immunosuppression, Placebo plus immunosuppression; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 70 Years
Enrollment: 757 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more

Conditions: Hypogammaglobulinemia
Interventions: CMV-Ig; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Antibody-mediated Rejection
Interventions: Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more

Conditions: Kidney Transplant, Delayed Graft Function
Interventions: Tacrolimus, Sirolimus; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
Interventions: Pirfenidone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions: Conditioning and Stem cell infusion; Combination Product
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

New Strategies for Non-invasive Detection of Chronic Allograft Nephropathy

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)

GI Reflux in Lung Transplant and Its Relationship to Chronic Rejection

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection

Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants